
April 26 (Reuters) - Pfizer Inc PFE.N:
PFIZER’S SASANLIMAB COMBINATION SIGNIFICANTLY IMPROVES EVENT-FREE SURVIVAL IN BCG-NAÏVE, HIGH-RISK NON-MUSCLE INVASIVE BLADDER CANCER
PFIZER INC - PHASE 3 CREST TRIAL SHOWS 32% RISK REDUCTION WITH SASANLIMAB
PFIZER INC - RESULTS SHARED WITH GLOBAL HEALTH AUTHORITIES FOR REGULATORY FILINGS
PFIZER INC - TRIAL MEETS PRIMARY ENDPOINT WITH SASANLIMAB COMBINATION